+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Jurkat cells, Primary antibody: P12115(RNF43 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

RNF43 (Ring Finger Protein 43) is a transmembrane E3 ubiquitin ligase that plays a critical role in regulating Wnt signaling pathways, primarily by targeting Frizzled receptors for lysosomal degradation. First identified as a tumor suppressor, RNF43 is frequently mutated in various cancers, including colorectal, endometrial, and pancreatic carcinomas. Its dysfunction leads to uncontrolled Wnt/β-catenin signaling, driving cell proliferation and tumorigenesis. Antibodies targeting RNF43 are essential tools for studying its expression, localization, and functional interactions in both normal physiology and disease contexts.

These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess RNF43 protein levels in tissues or cell lines. Given RNF43’s role in cancer, its antibodies also aid in identifying loss-of-function mutations or downregulation associated with poor prognosis. Additionally, they support research exploring RNF43’s interplay with other Wnt regulators, such as ZNRF3. and its involvement in stem cell maintenance and tissue homeostasis. Challenges in antibody development include specificity due to post-translational modifications and shared epitopes within the RING domain family. Recent advances in monoclonal antibody engineering have improved detection reliability, facilitating translational studies aimed at targeting RNF43-related pathways for cancer therapy or diagnostic applications.